MOONLAKE IMMUNOTHERAPEUTICS Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture of $12.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Shareholders' Equity
us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-09-30 was $3.71M, a 101.19% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-06-30 was $3.31M, a 81.02% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2025-03-31 was $2.29M, a 36.55% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for the quarter ending 2024-09-30 was $1.84M, a 29.27% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2025 was $12.90M, a 77.12% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2024 was $7.28M, a 2.48% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2023 was $7.11M, a 26.43% decline from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS shares granted, value, share-based payment arrangement, after forfeiture for fiscal 2022 was $9.66M.
| Period end | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 3 month as first filed | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 6 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 9 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 10 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month | Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $12.90M 10-K · filed 2026-02-25 | ||||||
| 2025-09-30 | $3.71M 10-Q · filed 2025-11-05 | $7.02M derived: sum of 2 quarters · filed 2026-08-10 | $9.31M derived: sum of 3 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $3.31M 10-Q · filed 2026-08-10 | $5.60M derived: sum of 2 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | $2.29M 10-Q · filed 2026-08-10 | ||||||
| 2024-12-31 | $7.28M 10-K · filed 2026-02-25 | $7.28M 10-K · filed 2025-02-26 | |||||
| 2024-09-30 | $1.84M 10-Q · filed 2025-11-05 | $1.84M 10-Q · filed 2024-11-07 | $3.67M derived: sum of 2 quarters · filed 2025-11-05 | $5.35M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $1.83M 10-Q · filed 2025-11-05 | $1.83M 10-Q · filed 2024-08-07 | $3.50M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $1.68M 10-Q · filed 2025-11-05 | $1.68M 10-Q · filed 2024-05-07 | |||||
| 2023-12-31 | $7.11M 10-K · filed 2026-02-25 | $7.11M 10-K · filed 2024-02-29 | |||||
| 2023-09-30 | $1.43M 10-Q · filed 2024-11-07 | $2.92M derived: sum of 2 quarters · filed 2024-11-07 | $5.50M derived: sum of 3 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $1.50M 10-Q · filed 2024-11-07 | $4.07M derived: sum of 2 quarters · filed 2024-11-07 | |||||
| 2023-03-31 | $2.58M 10-Q · filed 2024-11-07 | ||||||
| 2022-12-31 | $9.66M 10-K · filed 2025-02-26 | ||||||
| 2022-09-30 | $2.59M 10-Q · filed 2023-11-14 | $5.07M derived: sum of 2 quarters · filed 2023-11-14 | $7.06M derived: sum of 3 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $2.48M 10-Q · filed 2023-11-14 | $4.48M derived: sum of 2 quarters · filed 2023-11-14 | |||||
| 2022-03-31 | $1.99M 10-Q · filed 2023-11-14 | ||||||
| 2021-12-31 | $9.06M 10-K · filed 2023-03-20 | ||||||
| 2021-09-30 | $1.86M 10-Q · filed 2022-11-14 | $3.11M derived: sum of 2 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $1.25M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |